Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
IAG933 · 1 trial · 1 indication
Safety and tolerability of IAG933
Safety, tolerability and the maximum tolerated dose or recommended dose of IAG933
Tolerability of IAG933
| Arm | Type | Description |
|---|---|---|
| Group 1 | EXPERIMENTAL | Malignant pleural mesothelioma |
| Group 2 | EXPERIMENTAL | NF2 truncating mutations or deletions |
| Group 3 | EXPERIMENTAL | Solid tumors with functional YAP/TAZ fusions |
| Group 4 | EXPERIMENTAL | Non-pleural mesothelioma |
| Name | Type | Description |
|---|---|---|
| IAG933 | DRUG | Capsule |
Inclusion Criteria: 1. Signed informed consent must be obtained prior to participation in the study. 2. Male or female patients must be ≥ 18 years of age. 3. Dose escalation part: patients with histologically or cytologically confirmed diagnosis of advanced (unresectable or metastatic) mesothelioma...
IAG933 is an investigational small molecule being studied for the treatment of advanced mesothelioma and other solid tumors. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
IAG933 is being developed by Novartis AG, a multinational pharmaceutical company. Novartis is listed on the stock exchange under the ticker symbol NVS.
IAG933 is in Phase 1 clinical development. It is being evaluated in an active, not recruiting clinical trial for patients with advanced mesothelioma and other solid tumors. The drug is investigational and has not yet received regulatory approval.
IAG933 is being studied in a Phase 1 clinical trial with the identifier NCT04857372. This trial is enrolling patients with advanced mesothelioma and other solid tumors across multiple countries, including the United States, Australia, Canada, and several European and Asian nations.
No alternative names for IAG933 have been disclosed. The drug is identified solely by its investigational code name IAG933 in clinical trial records and development documentation.